Talha Badar and Team: New VTE Risk Prediction Model Validated for Asparaginase-Treated ALL
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X:
”Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALL
Happy to contribute in this effort by ALL NCTN:
High VTE rates persist in asparaginase-treated ALL despite prophylaxis.
Externally validated VTE risk model using D-dimer and hemoglobin at diagnosis.”
Read the full article here.
Title: Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALL
Authors: Daniela R. Anderson, Radhika Gangaraju, Wafik G. Sedhom, Eva N. Hamulyák, Tzu-Fei Wang, Kristen M O’Dwyer, Brian J. Carney, Chandrasekar Muthiah, Michaela Liedtke, Talha Badar, Shai Shimony, Renana Robinson, Kristen Sanfilippo, Andriy Derkach, Shira Naomi Dinner, Bart J. Biemond, David Nemirovsky, Leah A. Goldberg, Anjani D. Kapadia, Hannah Levavi, Michal Bar-Natan, Grace Van Hyfte, Karan Bansal, Marc Carrier, Jill Fulcher, Anke M. Gerrits, Mark R. Litzow, Selina M Luger, Guru Subramanian Guru Murthy, Marlise R. Luskin, Ofir Wolach, William Shomali, Jeffrey I. Zwicker, Wendy A Stock, Avi Leader
Stay updated with Hemostasis Today.
-
Jul 9, 2026, 12:41Thomas Palmer-Dench: Hexokinase Controls Platelet Activation and Hemostasis
-
Jul 9, 2026, 12:19Paschalis Evangelidis: Join Our Special Issue on Thrombosis and Vascular Disorders
-
Jul 9, 2026, 12:16Fernanda Betti Solano: Could Iron Deficiency Be Affecting Your Sleep?
-
Jul 9, 2026, 12:08Andreas Calatzis: What is the Rationale for Collagen-Induced Platelet Aggregation Testing?
-
Jul 9, 2026, 11:54Deepak Pradhan։ Can Withaferin-A Help Combat Drug-Resistant Malaria?
-
Jul 9, 2026, 11:26Peter Zhang: Is Canada Ready for the Gene Therapy Era?
-
Jul 9, 2026, 09:35Pradeebha Muthukumar: Do You Know the Signs of Anemia?
-
Jul 9, 2026, 09:24Maryam Majid: Machine Learning for Anemia Risk Prediction
-
Jul 9, 2026, 08:46Jordan Agay: Folate Deficiency in Patients Receiving PARP Inhibitors